Overview
Testicular seminomatous germ cell tumor, also known as testicular seminoma, is a malignant neoplasm arising from the germ cells of the testis. It is the most common single histological type of testicular germ cell tumor, accounting for approximately 40-50% of all testicular germ cell tumors. Seminomas originate from transformed gonocytes or undifferentiated spermatogonia within the seminiferous tubules and are frequently preceded by germ cell neoplasia in situ (GCNIS), formerly known as intratubular germ cell neoplasia. The disease primarily affects the male reproductive system, though advanced cases may metastasize to retroperitoneal lymph nodes, lungs, and other organs. The most common presenting symptom is a painless testicular mass or swelling, though some patients may experience testicular discomfort, heaviness in the scrotum, or dull aching in the lower abdomen or groin. Serum tumor markers, particularly elevated beta-human chorionic gonadotropin (beta-hCG) in some cases and lactate dehydrogenase (LDH), may be present, though alpha-fetoprotein (AFP) is characteristically not elevated in pure seminomas. Established risk factors include cryptorchidism (undescended testis), personal or family history of testicular germ cell tumor, testicular dysgenesis, and disorders of sex development. There is evidence of genetic susceptibility, with genome-wide association studies identifying multiple susceptibility loci including variants in KITLG, DMRT1, and other genes. Treatment is highly effective and depends on stage at diagnosis. Radical inguinal orchiectomy is the initial treatment for all stages. For early-stage disease, options include active surveillance, adjuvant radiotherapy, or single-agent carboplatin chemotherapy. Advanced-stage seminoma is treated with cisplatin-based combination chemotherapy, which achieves high cure rates. Overall, seminoma has an excellent prognosis, with five-year survival rates exceeding 95% for all stages combined.
Multifactorial
Caused by a mix of several genes and environmental factors
Adult
Begins in adulthood (age 18 or older)
Treatments
No FDA-approved treatments are currently listed for Testicular seminomatous germ cell tumor.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Testicular seminomatous germ cell tumor at this time.
New trials open frequently. Follow this disease to get notified.
Rare Disease Specialist
Rare Disease Specialist
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Testicular seminomatous germ cell tumor.
Community
No community posts yet. Be the first to share your experience with Testicular seminomatous germ cell tumor.
Start the conversation →Latest news about Testicular seminomatous germ cell tumor
No recent news articles for Testicular seminomatous germ cell tumor.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Testicular seminomatous germ cell tumor
What is Testicular seminomatous germ cell tumor?
Testicular seminomatous germ cell tumor, also known as testicular seminoma, is a malignant neoplasm arising from the germ cells of the testis. It is the most common single histological type of testicular germ cell tumor, accounting for approximately 40-50% of all testicular germ cell tumors. Seminomas originate from transformed gonocytes or undifferentiated spermatogonia within the seminiferous tubules and are frequently preceded by germ cell neoplasia in situ (GCNIS), formerly known as intratubular germ cell neoplasia. The disease primarily affects the male reproductive system, though advanc
How is Testicular seminomatous germ cell tumor inherited?
Testicular seminomatous germ cell tumor follows a multifactorial inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Testicular seminomatous germ cell tumor typically begin?
Typical onset of Testicular seminomatous germ cell tumor is adult. Age of onset can vary across affected individuals.
Which specialists treat Testicular seminomatous germ cell tumor?
19 specialists and care centers treating Testicular seminomatous germ cell tumor are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.